Eine einzigartige Partnerschaft mit einem Team aus Experten

Maksym Novikov, MD, is a Senior Medical Director for Fortrea, based in Maidenhead, United Kingdom. He serves as global lead project physician on assigned projects, providing medical expertise and support in the development and conduct of clinical trials. This includes reviewing feasibility of investigator sites and recruitment of trial subjects and performing feasibility risk assessment and data safety monitoring, develops and reviews protocols, case report forms and other data and materials on assigned projects. 

Dr. Novikov has more than 20 years of experience as a physician (surgeon), clinical researcher and medical director. Before Fortrea, he was Senior Medical Officer for Chiltern International in the UK. He also has held clinical research and medical monitoring positions with Novartis, AstraZeneca and other drug development and health care organizations. He joined Fortrea in April 2019.

Zehra Nurgul Pamuklar, MD, PhD, is a Senior Medical Director of Oncology for Fortrea, based in Cary, North Carolina. Dr. Pamuklar has more than 20 years of experience in oncology clinical drug development in biotechnology companies and CROs. She has supported planning and execution of global oncology clinical development projects from early phase to post approval, within medical affairs and clinical development organizations, and management of pharmaceutical, academic and regulatory interactions. 

Dr. Pamuklar graduated in medicine from the Ankara University School of Medicine, Ankara, Turkey; she has a PhD in Physiology/Immunophysiology and a Master of Science Degree in Clinical Research Management from Duke University, Durham, NC. 

Before joining our company in 2019, Dr. Pamuklar provided medical management of Phase I to Phase III immuno-oncology/oncology clinical trials in non-small cell lung cancer, hepatocellular carcinoma, bladder cancer, esophageal carcinoma, melanoma, pancreatic cancer, prostate cancer, urothelial cancer, colorectal cancer and head and neck cancer.

Lingjuan Pang, MD, is a Medical Director of oncology for Fortrea Clinical Development Service, based in Guangzhou, Guang Dong Province, China. Dr. Pang as a member of our global team of Medical Monitors has significant medical and pharmaceutical expertise with 14 years in the industry. She has vast knowledge of oncology therapeutic experience across Phase I-III. She has built strong relationships with external research groups and Key Opinion Leaders (KOLs) to which our experience and success ensures optimal performance in clinical tirals. 

Dr. Pang earned her master degree from Sun Yet-sen University, Guangzhou, Guangdong, China, major in oncology in 2005. She joined our company in Jan, 2021.

María Elvira Parellada, MD, ist als medizinische Leiterin im Bereich Onkologie von Fortrea in Buenos Aires, Argentinien beschäftigt. Dr. Parellada hat sich unserem Unternehmen im Jahr 2021 angeschlossen. Ihr Spezialgebiet ist die medizinische Überwachung onkologisch-hämatologischer Studien der Phase I bis III mit einem besonderen Fokus auf Zell- und Gentherapien und kleine Moleküle sowie deren Entwicklung durch Frühphasenstudien. Zuvor war Dr. Parellada als Wissenschaftlerin an zahlreichen onkologisch-hämatologischen Studien beteiligt und als MSL in großen pharmazeutischen Unternehmen beschäftigt. 

Sie hat ihren medizinischen Abschluss an der Universidad Nacional de Tucumán (Tucumán, Argentinien) erworben und ihre Facharztausbildung im Bereich Hämatologie im Hospital General de Agudos J. M. Ramos Mejía und in der Sociedad Argentina de Hematología (Buenos Aires, Argentinien) abgeschlossen.

As a member of our global team of Medical Monitors, Dr. Yi Pi has significant medical and pharmaceutical expertise with more than 15 years in the industry and academia. He was certificated for specialized clinical practice in Cardiac Surgery and internal Medicine of Cardiology and had performed as the Principal Investigator and Medical Monitor, fully engaged in both designing and implementing clinical research in China National Center for Cardiovascular Diseases, Fuwai hospital and Duke Clinical Research Institute. 

After joining our company in 2021, Dr. Pi has been working as lead/regional physician on multiply early phase studies, as well as confirmatory trials in treatment areas including Oncology, as well as Cardiology, Endocrinology, Respirology, Neurology, Dermatology and Rare Diseases. Dr. Pi earned his medical degree from Xiangya School of Medicine and Master of Health Science degree from Duke University School of Medicine.

Martine Poelman, MD, is an Executive Medical Director, Oncology, for Fortrea, based in Brussels, Belgium. She provides medical and scientific support to help advance drug development in hematological malignancies for Fortrea clients. Dr. Poelman brings more than 30 years of experience in clinical research and development as a physician and medical director, specializing in pediatrics and oncology, to Fortrea. Before assuming her current position, she served more than 15 years as Global Head of Oncology Research for Fortrea, providing medical monitoring for more than 200 clinical trials. Before joining Fortrea, she served as Clinical Research Physician, Hemato-Oncology-Infectiology, for Eli Lilly in Brussels. Vor ihrem Eintritt in die Forschung war sie als Ärztin für Knochenmarktransplantation und Hämatologie/Onkologie in der Abteilung für pädiatrische Onkologie des Wilhelmina Kinderkrankenhauses in den Niederlanden tätig. Martine joined our company in November 1996.

Suning Qian, MD, has eight years of pharmaceutical experience in oncology area and has built strong relationships with external research groups and Key Opinion Leaders. She has medical monitoring experience in all phases of oncology trials, focused on planning and execution of oncology clinical development projects. Dr. Qian earned her medical degree from Peking Union Medical College, Tsinghua University, and completed her internal medicine residency and fellowship training at Nanjing Drum Tower Hospital. She joined our company in July 2021.

Gong Qing, MD, ist Associate Medical Director der Abteilung Klinische Entwicklungsleistungen von Fortrea in Shanghai, China. Sie verfügt über mehr als 16 Jahre Erfahrung in der akademischen und klinischen Praxis und über 4 Jahre Erfahrung in der klinischen Entwicklungsforschung in der Früh- und Spätphase, darunter in der Onkologie und anderen Therapiebereichen. Ihre Branchenerfahrung umfasst globale Studien solider Tumore, einschließlich Brustkrebs, NSCLC und Bauchspeicheldrüsenkrebs, zur Entwicklung von Produkten für Biologics, gezielte Therapien und Chemotherapien. Vor Ihrer Karriere in der Branche war Dr. Gong als stellvertretende Chefärztin und seit 2018 in einem Pharmaunternehmen als medizinische Verantwortliche tätig. Sie hat sich unserem Unternehmen im März 2020 angeschlossen.

María García Requesens, MD, is a Medical Director at Fortrea based in Madrid, Spain. Dr. García has 5 years of experience in oncology clinical drug development clinical trials in pharma and CROs. She focuses on medical support of global oncology clinical trials for solid tumors. Dr. García earned her medical degree from Universidad Europea in Madrid. She also holds a Nursing Degree and is very patient-oriented, believing in the power of cross-functional communication. She joined Fortrea (formerly Labcorp) in January 2020.

Yulianna Tymovska, MD, PhD, is Senior Medical Director based in Brisbane, Australia. Dr. Tymovska has 20 years of clinical experience, specializing in Oncology (extensive clinical experience in breast, head and neck cancer, melanoma, and gynecology malignancies diagnostic and treatment, as well as research in mechanisms of tumors resistance to anti-cancer treatment and immune oncology). 

Dr. Tymovska has more than 15 years of clinical research experience as a clinical trial investigator and medical director (monitor) providing medical expert oversight and monitoring of clinical trials, contribution and scientific expertise to study design, and regulatory documents, work in cross functional team on all phases of the studies and trials including feasibility assessments, design process, education efforts, and management of medical information. 

Dr. Tymovska earned her medical degree and completed clinical oncology postgraduate training in Bogomolets National Medical University, Kyiv, Ukraine, and PhD training in Kavetsky IEPOR of NAS of Ukraine. She joined our company in Jan 2023.

Liang Wan, MD, PhD, is a Medical Director for Fortrea in Shanghai, China. He serves as lead project physician on clients’ drug development projects, provides medical/scientific expertise to project teams, reviews protocols and medical data, and is responsible for medical and safety monitoring on assigned projects. 

Dr. Wan verfügt über mehr als 25 Jahre Erfahrung als Arzt, klinischer Forscher und medizinischer Leiter sowie Behandlungserfahrung in den Bereichen Onkologie, Gastroenterologie und Hämatologie. Before joining Fortrea, he was Medical Director for IQVIA in Shanghai, serving as Global or Regional Medical Advisor on assigned projects. Er begann seine Karriere als Chirurg und klinischer Wissenschaftler am Rui Jin Hospital der Shanghai Jiao Tong University. Dr. Wan joined our company in May 2019.

Reigetsu Yoshikawa, MD, PhD, is a Senior Medical Director for Fortrea in Osaka, Japan. She contributes to the development of medical strategies and execution of clients' clinical programs and provides medical/scientific expertise to project teams. Dr. Yoshikawa has more than 30 years of experience as a physician, medical director/advisor, and professor of medicine in Japan. 

Before joining Fortrea, she was Senior Medical Advisor for Eli Lilly and previously served as Senior Medical Lead for Dainippon Sumitomo Pharma in Japan. Dr. Yoshikawa has served on the editorial boards of several peer-reviewed journals and has authored or co-authored dozens of articles, presentations, and abstracts. She joined our company in January 2021.